Uses of Epoetin for Anemia in Oncology
Jerome Seidenfeld, Margaret Piper, Carole R. Flamm, Naomi Aronson, United States. Agency for Healthcare Research and Quality, Blue Cross and Blue Shield Association. Technology Evaluation Center
Agency for Healthcare Research and Quality, U.S. Dept. of Health and Human Services, 2001 - Health & Fitness - 330 pages
59 pages matching characteristics of epoetin in this book
Results 1-3 of 59
What people are saying - Write a review
We haven't found any reviews in the usual places.
adverse events allogeneic analysis assessment autologous blood bone marrow ablation bone marrow transplantation Boogaerts Bukowski cancer patients cancer therapy Cella characteristics of epoetin chemotherapy Citation clinical compared concurrent controls control arms controlled trials disease dosing regimen double-blind effect of epoetin Elacebo control 91 enrolled patients epoetin administration epoetin alfa epoetin arm epoetin dose epoetin-treated patients etal evaluable evidence fatigue Fauser g/dL GM-CSF Hb level Hb threshold Hematol hematologic malignancies hematologic response hemoglobin higher quality studies Locatelli Lookup managing anemia mean Hb Mean/Median Baseline Hb median multiple myeloma myelodysplastic syndromes nonrandomized number of patients Oncology patients transfused pediatric percent percentage of patients radiation therapy radiotherapy randomized randomized controlled trials RBC engraftment RBC transfusion RBC units transfused recombinant human erythropoietin reticulocyte significant difference stem cells stem-cell transplant studies reported study arm subcutaneous systematic review transfused per patient transfusion outcomes treatment duration U/kg per week unblinded Yes Yes Yes Zecca